Advertisement
Industry News, Content and Resources2023-11-08T12:55:56-05:00

Industry News, Content and Resources

GSK Advances Oligonucleotide Research with Elsie Biotechnologies Platform License

GlaxoSmithKline (GSK) has solidified its commitment to oligonucleotide therapeutics by securing a nonexclusive license to Elsie Biotechnologies’ discovery platform following a successful research collaboration. This agreement, announced on Valentine’s Day, allows GSK to integrate Elsie’s technology and P(V) chemistry into its drug discovery efforts. While financial [...]

February 14th, 2024|Categories: Featured, HEOR Feature, Industry News|

Biogen CEO Optimistic Despite Financial Challenges, Eyes Growth with New Drug Launches

Chris Viehbacher, Biogen’s CEO, remains optimistic about the company’s future despite current financial difficulties. Biogen has experienced a decline in sales, with a 3% drop from 2022 to 2023, amounting to $9.8 billion. The company anticipates a further decrease in total revenue for 2024 but expects [...]

February 13th, 2024|Categories: Featured, HEOR Feature, Industry News|

FDA Approves Takeda’s Eohilia: A Breakthrough Oral Treatment for Eosinophilic Esophagitis

The U.S. Food and Drug Administration (FDA) recently approved Takeda's Eohilia, marking the introduction of the first oral medication for eosinophilic esophagitis (EoE) in the United States. EoE is a condition characterized by the inflammation of the esophagus, which can lead to symptoms such as vomiting, [...]

February 12th, 2024|Categories: Featured, HEOR Feature, Industry News|

Study Reveals Ebola Vaccine’s Potential to Save Lives Even After Infection

A recent study has provided significant insights into the efficacy of the Ebola vaccine, particularly in post-exposure scenarios. Conducted during the 2018-2020 Ebola Zaire outbreak in the Democratic Republic of the Congo, this research highlighted the vaccine's potential not only to prevent infections but also to [...]

February 12th, 2024|Categories: Featured, HEOR Feature, Industry News|

Pharma CEOs Defend Drug Pricing Practices at Senate Hearing Amid Calls for Reform

CEOs from Johnson & Johnson, Merck, and Bristol Myers Squibb testified before the Senate Health, Education, Labor, and Pensions Committee, chaired by Sen. Bernie Sanders, on the high cost of prescription drugs in the U.S. The hearing continued the dialogue on why American drug prices significantly [...]

February 9th, 2024|Categories: Featured, HEOR Feature, Industry News|

Kyverna Therapeutics Raises $319 Million in IPO, Advances Autoimmune Cell Therapy Research

Kyverna Therapeutics, under CEO Peter Maag, Ph., has recently completed a $319 million Initial Public Offering (IPO), marking a significant milestone for the biotech firm specializing in autoimmune-focused cell therapies. The company's stock closed at $30, notably higher than its opening price of $22 on Nasdaq. [...]

February 9th, 2024|Categories: Featured, HEOR Feature, Industry News|

Study Challenges Efficacy of High-Dose Naloxone in Opioid Overdose Survival, Raises Concerns Over Cost and Withdrawal Symptoms

A study published in the CDC's Morbidity and Mortality Weekly Report found no significant survival advantage for opioid overdose patients receiving an 8-milligram dose of naloxone over the standard 4-milligram dose. Despite pharmaceutical companies marketing higher-dose naloxone products amidst rising drug deaths and the prevalence of [...]

February 8th, 2024|Categories: Featured, HEOR Feature, Industry News|

Eli Lilly Settles Lawsuit with Minnesota to Cap Insulin Prices at $35 and Donate to Clinics

Eli Lilly has agreed to a settlement to provide low-cost insulin to Minnesota patients, addressing a lawsuit accusing it and two other major insulin manufacturers of deceptive price inflation. Under the agreement, filed in a New Jersey federal court, Lilly will cap out-of-pocket expenses for its [...]

February 8th, 2024|Categories: Featured, HEOR Feature, Industry News|

Gilead Halts Magrolimab Blood Cancer Development After Increased Mortality Risk

Gilead Sciences is halting the development of magnolia for blood cancer, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), following an "increased risk of death" observed in a late-stage trial. This decision comes after the FDA placed a full clinical hold on the studies, stemming [...]

February 7th, 2024|Categories: Featured, HEOR Feature, Industry News|

Joshua Boger Takes Chair at CervoMed, Eyes Potential Breakthrough in Dementia Treatment with Neflamapimod

Joshua Boger, the former CEO of Vertex Pharmaceuticals, has selectively accepted a new role as chair of CervoMed. This company piqued his interest with its development of neflamapimod for dementia. Neflamapimod, initially developed by Vertex for a different purpose, targets a kinase called p38α and has [...]

February 7th, 2024|Categories: Featured, HEOR Feature, Industry News|

House Hearing Addresses Drug Shortages and Manufacturing Challenges in the U.S.

At a House Ways and Means Committee hearing, the issue of chronic drug shortages in the U.S., exacerbated by questionable generic drug manufacturing and low prices, was examined. Committee Chair Jason Smith highlighted poor manufacturing quality as a primary and preventable cause of these shortages. Experts, [...]

February 6th, 2024|Categories: Featured, HEOR Feature, Industry News|

AstraZeneca Invests $300 Million in New Cell Therapy Facility in Maryland, Creating Over 150 Jobs

AstraZeneca announced a $300 million investment in a new facility in Rockville, Maryland, dedicated to discovering and developing cell therapies. This initiative will create more than 150 jobs in the United States and initially concentrate on manufacturing cell therapies for clinical trials, possibly expanding to support [...]

February 6th, 2024|Categories: Featured, HEOR Feature, Industry News|

Key Insights from the 2025 Medicare Advantage Proposals: A Cautious Approach in an Election Year

The 2025 Medicare Advantage (MA) proposals introduced by CMS indicate a cautious approach by the Biden administration, with an average benchmark payment decrease of 0.2%. This decrease is not expected to result in actual payment reductions to MA plans due to the industry’s practice of intensive [...]

February 5th, 2024|Categories: Featured, HEOR Feature, Industry News|

The Rise of GLP-1 Influencers: Celebrity Endorsements and Social Media’s Role in the Ozempic Weight Loss Craze

The "Ozempic craze" refers to the growing popularity of GLP-1 drugs for weight loss, driven by endorsements from celebrities and influencers. These drugs, including Novo Nordisk's Ozempic and Wegovy and Eli Lilly's Mounjaro and Zepbound, have seen a surge in demand, partly due to mentions by [...]

February 5th, 2024|Categories: Featured, HEOR Feature, Industry News|

Keytruda Surpasses Comirnaty to Become World’s Top-Selling Drug in 2023

Merck’s Keytruda has emerged as the world’s top-selling drug in 2023, with sales reaching $25 billion, surpassing Pfizer and BioNTech’s Comirnaty, which led the previous two years. Keytruda’s success marks a significant milestone, outperforming long-time leaders like AbbVie’s Humira and Pfizer’s Lipitor. The PD-1 inhibitor’s growth [...]

February 2nd, 2024|Categories: Featured, HEOR Feature, Industry News|
Go to Top